Working… Menu
Trial record 4 of 129 for:    Venetoclax AND Relapsed

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03739554
Recruitment Status : Recruiting
First Posted : November 14, 2018
Last Update Posted : January 29, 2019
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Cyclacel Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 15, 2020
Estimated Study Completion Date : May 15, 2020